Skip to main content

Table 2 Ongoing phase 3 clinical trials for advanced stage or unresectable hepatocellular carcinoma

From: Emerging agents and regimens for hepatocellular carcinoma

Trial

Lines

Arms

Clinicaltrials.gov identifier

Sponsor

IMbrave150

First line

Atezolizumab + bevacizumab vs sorafenib

NCT03434379

Roche

 

First line

Tislelizumab vs sorafenib

NCT03412773

BeiGene

ZGDH3

First line

Donafenib vs sorafenib

NCT02645981

Zelgen

HIMALAYA

First line

Durvalumab or durvalumab + tremelimumab vs sorafenib

NCT03298451

AstraZeneca

LEAP-002

First line

Lenvatinib + pembrolizumab vs lenvatinib

NCT03713593

MSD + Eisai

COSMIC-312

First line

Cabozantinib + atezolizumab vs sorafenib vs cabozantinib

NCT03755791

Exelixis

SHR-1210-III-310

First line

Camrelizumab + apatinib vs sorafenib

NCT03764293

Hengrui

ORIENT-32

First line

Sintilimab + IBI305 vs sorafenib

NCT03794440

Innovent

PHOCUS

First line

Pexa-Vec followed by sorafenib vs sorafenib

NCT02562755

SillaJen

KEYNOTE-394

Second line

Pembrolizumab vs placebo in Asian pts.

NCT03062358

MSD

AHELP

Second line

Apatinib vs placebo

NCT02329860

Hengrui